Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy

Journal of Nuclear Medicine

Volumn 49, Issue 7, 2008, Pages 1090-1096

  Sotgia, Barbara ^a   Sciagrà, Roberto ^a,d   Olivotto, Iacopo ^a   Casolo, Giancarlo ^b   Rega, Luigi ^a   Betti, Irene ^a   Pupi, Alberto ^a   Camici, Paolo G ^c   Cecchi, Franco ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Ospedale Versilia   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Coronary microvascular dysfunction; Fibrosis; Hyperthrophic cardiomyopathy; Myocardial blood flow; Positron emission tomography

Indexed keywords

AMMONIA N 13; DIPYRIDAMOLE; GADOLINIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE FIBROSIS; HUMAN; HYPEREMIA; HYPERTROPHIC CARDIOMYOPATHY; ISOTOPE LABELING; MALE; MICROANGIOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AMMONIA; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; CORONARY CIRCULATION; DIPYRIDAMOLE; FEMALE; FIBROSIS; HUMANS; HYPEREMIA; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIUM; NITROGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY;

EID: 46749099836     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.050138     Document Type: Article

References (40)

1. Elliott P, McKenna W. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881-1891.
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.
3. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476-482.
4. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545-557.
5. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 1987;75:1130-1139.
6. Factor SM, Butany J, Sole MJ, Wigle ED, Williams WC, Rojkind M. Pathological fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;17:1343-1351.
7. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36-44.
8. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol. 1979;43:1086-1102.
9. Pasternac A, Noble J, Streulens Y, Elie R, Henschke C, Bourassa MG. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation. 1982;65:778-789.
10. Cannon RO III, Schenke WH, Maron BJ, et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:53-62.
11. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol. 2000;31:988-998.
12. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830-840.
13. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027-1035.
14. Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodelling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;47:1043-1048.
15. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-1567.
16. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156-2164.
17. Kaufmann PA, Camici PG. Myocardial blood flow by PET: technical aspects and clinical applications. J Nucl Med. 2005;46:75-88.
18. Camici P, Chiaritti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol. 1991;17:879-886.
19. Camici PG, Cecchi F, Gistri R, et al. Dipyridamole-induced subendocardial underperfusion in hypertrophic cardiomyopathy assessed by positron emission tomography. Coron Artery Dis. 1991;2:837-841.
20. Choudhury L, Elliott P, Rimoldi O, et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol. 1999;94:49-59.
21. Lorenzoni R, Gistri R, Cecchi F, et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am Heart J. 1998;136:972-981.
22. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, and European Society of Cardiology Committee for Practice Guidelines. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003;24:1965-1991.
23. Knaapen P, van Dockum WG, Bondarenko O, et al. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. J Nucl Med. 2005;46:923-929.
24. Knaapen P, van Dockum WG, Götte MJ, et al. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study. J Nucl Cardiol. 2006;13:660-667.
25. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Circulation. 1997;95:1686-1744.
26. Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74:363-368.
27. Cardiac Modeling PMODE (PCARD). User guide. Available at: http://www.pmod.com/technologies/doc/pcard/toc.htm. Accessed May 30, 2008.
28. Cerqueira MD, Weissman NJ, Dilsizian V, et al. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542.
29. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol. 1990;15:1032-1042.
30. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215-223.
31. Ichikawa Y, Sakuma H, Suzawa N, et al. Late gadolinium-enhanced magnetic resonance imaging in acute and chronic myocardial infarction improved prediction of regional myocardial contraction in the chronic state by measuring thickness of nonenhanced myocardium. J Am Coll Cardiol. 2005;45:901-909.
32. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 2001;103:2780-2783.
33. Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418-2425.
34. Wu E, Wu E, Judd RM, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet. 2001;357:21-28.
35. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-225.
36. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88:275-279.
37. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001;104:1380-1384.
38. Lombardi R, Betocchi S, Losi MA, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108:1455-1460.
39. Bogaert J, Goldstein M, Tannouri F, Golzarian J, Dymarkowski S. Original report: late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. AJR. 2003;180:981-985.
40. 13N]ammonia and PET. Am J Physiol Imaging. 1989;4:97-104.